The emergence of drug-resistant viruses in patients receiving long-term therapy is a major problem in the treatment of AIDS. Variants of human immunodeficiency virus type 1 (HIV-1) resistant to 3'-azido-3'-deoxythymidine (zidovudine; AZT), 2',3'-dideoxyinosine (ddI), and 2',3'-dideoxycytidine (ddC) have been isolated from patients receiving therapy (1, 7, 8, 14) , while those resistant to AZT (2, 6 ) and pyridinone drugs (11) have also been isolated by selecting for growth in the presence of the drug in cell culture. It is important to know whether resistance will arise against new drugs and to know the frequency and types of mutations that are needed to render HIV resistant to a given drug. Furthermore, the identification of residues involved in drug resistance may throw light on the architecture of the catalytic site to help design better, efficacious drugs. Previously, we described an in vitro screen employing a bacterially expressed HIV reverse transcriptase (RT) to expedite the identification of mutations that render RT resistant to substrate analog drugs (12, 13, 15) . The procedure yielded a variant RT, ddGTPr_1, in which the alteration of a glutamic acid at the 89th position to glycine rendered the enzyme resistant to phosphonoformic acid (PFA; foscarnet) and several deoxynucleoside triphosphate (dNTP) analog inhibitors including ddGTP, ddATP, ddCTP, ddTTP, and 2',3'-dideoxy, 3'-azidothymidine triphosphate (AZTTP). The mutant RT, unlike the wild-type enzyme, displayed a lack of preference for magnesium. On the basis of these results, we speculated that the 89th residue in the wild-type RT may be involved in dNTP binding (13) . Although the sequence around the 89th residue is in a region of HIV RT that is not highly conserved among retroviral RTs, it is well-conserved among lentiviruses. In this communication, we describe the effects on nucleoside analog sensitivity of amino acid residues other than glycine at the 89th residue in HIV-1 RT and show that an identical mutation introduced into HIV-2 RT leads to a very similar phenotype.
Mutagenesis at the 89th codon. In trying to understand the which showed a higher fold increase in the IC50. Therefore, it appears that replacements of Glu-89 with hydrophilic or polar amino acids have minimal or no effect on the sensitivity to inhibition by ddGTP. When tested with several inhibitors, the original mutant E89G was most resistant to ddGTP and PFA. Therefore, the panel of mutants were also tested for inhibition by PFA in the standard assay as described for ddGTP. The IC50s were determined as described above, and the fold increases are shown in Table 1 expression plasmid encoding a TrpE-HIV-2 RT fusion protein was created by cloning a 1.82-kb Bsu36I (flush-ended with Klenow enzyme)-HincII fragment from the pHIV-2 ROD clone (provided by Keith Peden, National Institutes of Health, Bethesda, Md.) into the SmaI site of the pATH2 vector. In the fusion gene thus created, the trpE sequences are followed by the HIV-2 sequence in which RT is flanked by seven residues of protease and 43 residues of integrase.
The bacteria carrying this construct were induced for expression by tryptophan starvation, and the bacterial lysates were prepared and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. Figure 1 shows the accumulation of an approximately 112-kDa fusion protein in bacteria carrying the HIV-2 RT expression plasmid. Enzymatic assays of lysates showed that both RNA-dependent DNA polymerase and the RNase H activities (data not shown) were present.
We first examined whether HIV-1 and HIV-2 RTs differed in their sensitivities to ddGTP and PFA. Lysates of bacteria carrying each of the expression plasmids were used in standard reactions to measure the extent of inhibition. The patterns of inhibition, shown in Fig. 2a, HIV-2 RT by oligonucleotide-directed mutagenesis of an M13 version of the HIV-2 RT clone. The mutation was reintroduced into the expression plasmid (HIV-2 RT E89G), the mutant protein was induced, and lysates were prepared and tested for sensitivity to inhibition by both ddGTP and PFA alongside the wild-type HIV-2 enzyme. Figure 2b shows the patterns of inhibition by ddGTP and PFA for both the wild-type and mutant HIV-2 RTs. Interestingly, Glu-89 -* Gly alteration in HIV-2 RT caused a decrease in sensitivity to both drugs as did the Glu-89 --Gly version of HIV-1 RT (fold increases of -22 for ddGTP and -50 for PFA; Table 2 ).
We have shown here that the nature of the amino acid side chain at the 89th position of the HIV-1 RT sequence has a minimal effect on the enzymatic properties of this enzyme but plays a significant role in rendering it ddGTP or PFA resistant. It is interesting that no alteration of the 89th residue abolished the enzymatic activity of HIV-1 RT. In fact, when mutations A, E, S, T, and K were reconstructed into infectious molecular clones of HIV-1 and introduced into CD4+ T lymphocytes, no deleterious effect on viral replication was seen (lOa). A lack of conservation for a residue leading to profound effects upon genetic alteration is not entirely unprecedented, as mutations in RT of ddC-, ddI-, and AZT-resistant variants of HIV are also located in poorly conserved regions (1, 8, 14) . The lack of conservation and the fact that alteration does not affect enzymatic activity may suggest that the 89th residue is not critical for catalytic function and that it probably serves some secondary function. On the other hand, although not necessarily conserved, the role of this residue on nucleoside analog sensitivity suggests a crucial position for this residue in the dNTPbinding pocket of this enzyme (see below).
Many of the replacements tested here lead to resistance to both ddGTP and PFA. The fact that the presence of hydrophobic residues at the 89th position leads to a greater resistance is intriguing. It is tempting to speculate that the presence of a hydrophobic or a hydrophilic residue determines the strength of interaction between the dNTP-binding pocket of RT (1, 8, 14) , and residues 185 and 186 (which are actually at the catalytic site) and the fact that the Glu-89 is at the juncture of the finger and palm subdomains suggest its likely participation in forming the template-binding site. Until proven, this remains speculative. Other interpretations of our results, such as a distance effect on another residue directly involved in binding to ddGTP, cannot be completely ruled out at present. Several residues involved in sensitivity of HIV-1 RT to AZTlTP have been previously identified (9, 10) . These include amino acid residues Asp-113, Ala-114, Tyr-115, Lys-55, and Gln-151. Furthermore, a separate set of residues, Asp-67, Asp-69, Lys-70, Leu-74, and Thr-215, lead to AZT and ddI resistance in HIV (1, 8, 14) . It is interesting that most of these mutations along with Glu-89 are clustered in a 100-amino-acid region of HIV-1 RT. All or some of these residues together may form the nucleotide-binding pocket of the HIV RT.
Furthermore, our results show that the mutation that rendered HIV-1 RT resistant to ddGTP, when introduced into the RT of a related virus, brings about a very similar phenotype. This suggests that the Glu-89 residue plays similar roles in the RT of both these viruses, although the two differ significantly in their overall amino acid sequences.
